Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy

Citation
V. Heiser et al., Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy, P NAS US, 97(12), 2000, pp. 6739-6744
Citations number
28
Categorie Soggetti
Multidisciplinary
Journal title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
ISSN journal
00278424 → ACNP
Volume
97
Issue
12
Year of publication
2000
Pages
6739 - 6744
Database
ISI
SICI code
0027-8424(20000606)97:12<6739:IOHFBS>2.0.ZU;2-3
Abstract
The accumulation of insoluble protein aggregates in intra and perinuclear i nclusions is a hallmark of Huntington's disease (HD) and related glutamine- repeat disorders. A central question is whether protein aggregation plays a direct role in the pathogenesis of these neurodegenerative diseases. Here we show by using a filter retardation assay that the mAb 1C2. which specifi cally recognizes the elongated polyglutamine (polyQ) stretch in huntingtin, and the chemical compounds Congo red, thioflavine S. chrysamine G, and Dir ect fast yellow inhibit HD exon 1 protein aggregation in a dose-dependent m anner. On the other hand. potential inhibitors of amyloid-beta formation su ch as thioflavine T. gossypol, melatonin, and rifampicin had little or no i nhibitory effect on huntingtin aggregation in vitro. The results obtained b y the filtration assay were confirmed by electron microscopy, SDS/ PAGE, an d MS. Furthermore. cell culture studies revealed that the Congo red dye at micromolar concentrations reduced the extent of HD exon 1 aggregation in tr ansiently transfected COS cells. Together, these findings contribute to a b etter understanding of the mechanism of huntingtin fibrillogenesis in vitro and provide the basis for the development of new huntingtin aggregation in hibitors that may be effective in treating HD.